In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)

Date: May 17, 2021 Issue #:  1624Summary:  On April 23, 2021, on advice from the Advisory Committee on Immunization Practices (ACIP), the FDA and CDC recommended that use of the Johnson& Johnson adenovirus-based COVID-19 vaccine resume despite its association with development of thrombosis with thrombocytopenia syndrome (TTS). Administration of the vaccine had been paused on April 13 because of 6 reports of TTS, but after completing a data review that identified a further 9 cases associated with the formulation, the agencies concluded that the benefits of the vaccine outweighed its risks. About 7.98 million doses of the single-dose vaccine had been administered in the US at the time of the review.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: COVID-19 vaccines Source Type: research